Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares

Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton sold 25,107 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $0.56, for a total transaction of $14,059.92. Following the sale, the chief executive officer now directly owns 242,591 shares in the company, valued at approximately $135,850.96. This represents a 9.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Athira Pharma Price Performance

ATHA stock traded up $0.02 during mid-day trading on Friday, reaching $0.57. 127,376 shares of the company’s stock were exchanged, compared to its average volume of 218,238. The company has a market cap of $22.16 million, a price-to-earnings ratio of -0.20 and a beta of 2.99. Athira Pharma, Inc. has a 12-month low of $0.41 and a 12-month high of $4.30. The stock’s 50 day moving average is $0.61 and its 200 day moving average is $1.52.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. On average, research analysts forecast that Athira Pharma, Inc. will post -2.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Mizuho lowered Athira Pharma from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $5.00 to $0.50 in a research note on Thursday, September 19th.

Institutional Trading of Athira Pharma

Institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP increased its position in shares of Athira Pharma by 909.8% during the third quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock worth $177,000 after purchasing an additional 357,787 shares in the last quarter. Bristlecone Advisors LLC lifted its holdings in Athira Pharma by 295.6% in the 3rd quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock valued at $151,000 after purchasing an additional 252,200 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Athira Pharma by 25.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock worth $1,458,000 after purchasing an additional 111,759 shares during the last quarter. Invst LLC purchased a new stake in shares of Athira Pharma during the second quarter worth $68,000. Finally, Forefront Analytics LLC lifted its stake in shares of Athira Pharma by 126.0% in the second quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after buying an additional 25,979 shares in the last quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.